Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Mar;37(3):265–272. doi: 10.1111/j.1365-2125.1994.tb04274.x

Dose finding studies with imidapril--a new ACE inhibitor.

M J Vandenburg 1, E M Mackay 1, I Dews 1, T Pullan 1, S Brugier 1
PMCID: PMC1364758  PMID: 8198936

Abstract

1. We describe an approach involving a smaller, shorter study, leading onto a longer, larger study in which the antihypertensive effects of ascending doses of imidapril, a new ACE inhibitor, were investigated. Both studies were planned prospectively, assuming a clinically useful fall in BP to be 8 mm Hg (s.d. = 9). The studies included patients with mild to moderate essential hypertension (baseline sitting diastolic blood pressure (SDBP) 95-115 mm Hg). After a placebo run-in of 2-3 weeks patients received either placebo or imidapril 2.5, 5, 10 or 20 mg in the 2 week study (n = 91) or imidapril 5, 10, 20 or 40 mg in the 4 week study (n = 162). 2. The overall mean baseline SDBP was 103.4 mm Hg (s.d. 0.62) in the initial study and 101.5 mm Hg (s.d. 0.41) in the 4 week study. 3. Compared with placebo, imidapril 10, 20 and 40 mg significantly reduced SDBP. There was no significant difference between these doses, suggesting that 10 mg achieved maximal ACE inhibition in most patients. The 2.5 mg dose showed no significant effect. The 5 mg dose gave an intermediate effect. In both studies the overall incidence of adverse events was similar in the imidapril and placebo groups, and was not worrying.

Full text

PDF
267

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson A. B., Robertson J. I. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836–839. doi: 10.1016/s0140-6736(79)92186-x. [DOI] [PubMed] [Google Scholar]
  2. Ball S. G., Robertson J. I. A need for new converting enzyme inhibitors? Br Med J (Clin Res Ed) 1985 Jan 19;290(6463):180–181. doi: 10.1136/bmj.290.6463.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Belz G. G., Kirch W., Kleinbloesem C. H. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet. 1988 Nov;15(5):295–318. doi: 10.2165/00003088-198815050-00003. [DOI] [PubMed] [Google Scholar]
  4. Bravo E. L., Tarazi R. C. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979 Jan-Feb;1(1):39–46. doi: 10.1161/01.hyp.1.1.39. [DOI] [PubMed] [Google Scholar]
  5. FREIS E. D. Hemodynamics of hypertension. Physiol Rev. 1960 Jan;40:27–54. doi: 10.1152/physrev.1960.40.1.27. [DOI] [PubMed] [Google Scholar]
  6. Fagard R., Amery A., Lijnen P., Reybrouck T. Haemodynamic effects of captopril in hypertensive patients: comparison with saralasin. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):131s–134s. doi: 10.1042/cs057131s. [DOI] [PubMed] [Google Scholar]
  7. Frohlich E. D., Cooper R. A., Lewis E. J. Review of the overall experience of captopril in hypertension. Arch Intern Med. 1984 Jul;144(7):1441–1444. [PubMed] [Google Scholar]
  8. Lund-Johansen P. Haemodynamics in essential hypertension. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):343s–354s. doi: 10.1042/cs059343s. [DOI] [PubMed] [Google Scholar]
  9. MacGregor G. A., Markandu N. D., Roulston J. E., Jones J. C. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme. Br Med J. 1979 Nov 3;2(6198):1106–1109. doi: 10.1136/bmj.2.6198.1106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Vidt D. G., Bravo E. L., Fouad F. M. Medical intelligence drug therapy: captopril. N Engl J Med. 1982 Jan 28;306(4):214–219. doi: 10.1056/NEJM198201283060405. [DOI] [PubMed] [Google Scholar]
  11. de Bruyn J. H., Man in't Veld A. J., Wenting G. J., Derkx F. H., Schalekamp M. A. Haemodynamic profile of captopril treatment in various forms of hypertension. Eur J Clin Pharmacol. 1981;20(3):163–168. doi: 10.1007/BF00544593. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES